Core Viewpoint - Immune checkpoint blockade (ICB) therapy has shown promise in improving clinical outcomes for some head and neck squamous cell carcinoma (HNSCC) patients, but the mechanisms regulating treatment response remain poorly understood [3][6]. Group 1: Role of Gut Microbiome - Increasing research emphasizes the significant role of the gut microbiome in determining the effectiveness of immunotherapy, with specific gut bacteria shown to enhance anti-tumor immunity and T cell proliferation in cancer patients [3]. - Intratumoral bacteria have been identified as immunosuppressive and promote resistance to ICB therapy in HNSCC [4]. Group 2: Research Findings - A study analyzing samples from the CIAO clinical trial found that only the total abundance of intratumoral bacteria could predict patient response to ICB therapy, a conclusion validated across multiple independent cohorts [6]. - High abundance of intratumoral bacteria correlates with an immunosuppressive tumor microenvironment characterized by neutrophil accumulation and reduced T cells and other adaptive immune cells [6]. - Experimental manipulation of intratumoral bacterial abundance in a mouse model of HNSCC replicated the immunological associations observed in clinical trial participants [6]. Group 3: Implications for Immunotherapy - The findings indicate that high levels of intratumoral bacteria are a key inhibitory factor for anti-tumor immunity and contribute to resistance against immunotherapy [7].

Core Viewpoint - The article discusses the significant burden of cardiovascular metabolic diseases (CMD), particularly cardiovascular disease (CVD) and type 2 diabetes (T2D), linked to poor dietary habits and the human gut microbiome. It emphasizes the need for a comprehensive understanding of how diet influences gut microbiota and health outcomes, leading to the development of the "2025 ZOE Microbiome Health Ranking" system [1][2][3]. Group 1: Importance of Gut Microbiome - CMD, including CVD and T2D, has become a major global health burden, prompting scientists to focus on the human gut microbiome as a key link between diet and health [6]. - The gut microbiome acts as a "factory" that converts food into various metabolites, affecting the host's physiological state, but defining a universal standard for a "healthy gut microbiome" remains a challenge due to individual variability [6][8]. Group 2: Research Findings - The study analyzed gut microbiomes from over 34,000 individuals, establishing a comprehensive health evaluation system that correlates gut microbiota with health indicators like body mass index (BMI) and disease status [2][8]. - The "2025 ZOE Microbiome Health Ranking" was created by ranking 661 common species based on their association with 37 health markers, where lower rankings indicate beneficial bacteria and higher rankings indicate harmful bacteria [11][12]. Group 3: Practical Implications - The ranking system has shown significant correlations with BMI, where individuals with a normal BMI carry more beneficial bacteria compared to those who are obese [16]. - Analysis of public data from 25 diseases confirmed that healthy individuals have a higher abundance of beneficial bacteria compared to those with diseases, indicating that gut microbiome imbalance is a common feature across various health conditions [17]. Group 4: Dietary Interventions - Two clinical trials demonstrated that personalized dietary interventions can effectively increase the abundance of beneficial bacteria while reducing harmful bacteria, supporting the idea that diet can shape gut microbiota towards healthier states [19]. - The findings suggest a pathway towards "precision nutrition," where dietary recommendations can be tailored based on individual gut microbiome characteristics to optimize health outcomes [22][23].

Core Viewpoint - The study highlights the role of the oral symbiotic bacterium Veillonella in promoting Clostridioides difficile infection (CDI) in patients with Crohn's disease by inhibiting bile acid transport protein ASBT, leading to abnormal bile acid accumulation in the intestine [3][9]. Group 1: Disease Overview - Crohn's disease is a common inflammatory bowel disease (IBD) characterized by abdominal pain, diarrhea, and intestinal obstruction, affecting the entire digestive tract with a high postoperative recurrence rate of approximately 80% [2]. - The global prevalence of IBD was 0.75% as of 2020, projected to rise to 1.0% by 2030, with 37%-59% of IBD cases being Crohn's disease [2]. Group 2: Research Findings - The research published in Cell Host & Microbe indicates that Veillonella intestinal colonization promotes CDI in Crohn's disease patients [3]. - Veillonella parvula inhibits the expression of the bile acid transport protein ASBT, preventing bile acid reabsorption and causing abnormal bile acid accumulation in the intestine, which triggers CDI [9][12]. - The study found a correlation between the abundance of Veillonella and increased bile acid metabolism in Crohn's disease patients, suggesting that the presence of bile acids can facilitate the germination of C. difficile spores [9][12].

Core Viewpoint - Exercise is recognized as a significant factor in reducing cancer risk, enhancing the survival of cancer patients, and improving treatment outcomes, particularly through its effects on the gut microbiome and immune response [2][4][6]. Group 1: Research Findings - A study published in the journal Cell indicates that exercise induces the production of the gut microbiota metabolite formate, which enhances CD8 T cell antitumor immunity and improves the efficacy of cancer immunotherapy [3][4]. - The research highlights that the gut microbiome's metabolic products, rather than the microbiome itself, are crucial for the antitumor effects of exercise [9][10]. - The study identifies Nrf2 as a key mediator in the enhancement of Tc1 cell function driven by formate, both in vitro and in vivo [11]. Group 2: Implications for Cancer Treatment - The findings suggest that high-producing formate gut microbiota in humans can enhance tumor suppression and promote robust antitumor Tc1 immune responses, indicating formate as a potential biomarker for enhancing Tc1-mediated antitumor immunity [12][15]. - The research opens avenues for developing treatment strategies that combine exercise with microbiota-derived metabolites, particularly focusing on Nrf2 agonists like formate for patients resistant to immune checkpoint inhibitors [16][17].

Core Viewpoint - The interaction between diet, phytochemicals, gut microbiome, and the liver significantly influences the anticancer activity of PI3K inhibitors, challenging previous assumptions about the role of macronutrients in this process [2][11]. Group 1: PI3K Inhibitors and Cancer Treatment - PI3K signaling pathway is crucial in insulin action and is frequently activated in human cancers, with approved PI3K inhibitors used for treating leukemia, lymphoma, and breast cancer [2]. - Preclinical studies indicate that ketogenic diets can enhance the efficacy of PI3K inhibitors in cancer treatment, although the underlying mechanisms were previously unclear [2][5]. - A recent study published in Cell reveals that the synergistic anticancer effect of ketogenic diets and PI3K inhibitors is not related to macronutrient composition but rather to the metabolism of dietary phytochemicals by gut microbiota [3][7]. Group 2: Role of Diet and Gut Microbiome - Dietary interventions can influence disease progression and drug response, with various diets shown to slow tumor growth and enhance anticancer drug activity in preclinical models [5]. - The study highlights that the differences in diets extend beyond macronutrient composition, emphasizing the importance of phytochemicals and their interactions with gut microbiota [6][8]. - Gut microbiota can metabolize phytochemicals from the diet, leading to the production of metabolites that affect drug metabolism and efficacy [7][9]. Group 3: Key Findings of the Study - Purified rodent diets can sensitize tumors to PI3K inhibitors independently of macronutrient composition [9]. - The sensitizing effect involves changes in drug metabolism by liver cytochrome P450 enzymes [9]. - Specific phytochemicals, such as soyasaponins, are metabolized by gut microbiota into compounds that can reduce the levels and activity of PI3K inhibitors [9][11].